{"version":"1.0","type":"link","title":"Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer.","author_name":"Rajendran R 외","author_url":"https://prs-insight.online/author/Rajendran%20R","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/136598","thumbnail_width":1200,"thumbnail_height":630}